ProQR Therapeutics Q1 Revenue Plummets, Missing Estimates by Over 60%
Summary
ProQR Therapeutics reported Q1 revenue of €2.03 million, significantly missing analyst estimates of €5.25 million, representing a miss of over 60%. The company also reported a wider net loss of €13.4 million, up from €10.1 million a year prior. This news follows the company's 6-K filing earlier today which announced Q1 2026 financial results, but did not detail the magnitude of the revenue miss or the specific analyst consensus. The substantial revenue miss is a material negative development for this small-cap biotechnology company, likely impacting investor confidence and stock performance despite a cash runway into mid-2027. Traders will monitor the company's progress on its pipeline, specifically the AX-0810 target engagement data in Q2 2026 and initial clinical data from the biliary atresia trial in China in H1 2027, as these could be future catalysts.
At the time of this announcement, PRQR was trading at $1.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $169.6M. The 52-week trading range was $1.33 to $3.10. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.